Prolacta Bioscience Fortifiers Reduce Risk of Serious Lung Disease and Hospital Costs Among Premature Infants, Compared to Cow Milk-Based Fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD)
Research Suggests Some Premature Infants May Go Home from the NICU Up to 3 Weeks Earlier When Fed Prolacta’s 100% Human Milk-Based Nutritional Products; Those with Bronchopulmonary Dysplasia May Benefit the Most
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Length of hospital stay
Multiple NICUs Showed Improved Growth & Lung Health in Premature Infants by Fortifying Feeds Safely in the First Days of Life with Prolacta’s 100% Human Milk-Based Fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Early Fortification Feeding Protocols Growth Necrotizing Entercolitis (NEC) Product
Understanding Bronchopulmonary Dysplasia (BPD)
Type: Blog
Topic(s): Bronchopulmonary Dysplasia (BPD)
Donor Human Milk Protects Against Bronchopulmonary Dysplasia | Latch
Type: Blog
Topic(s): Bronchopulmonary Dysplasia (BPD) Feeding Intolerance Feeding Protocols Healthcare Professionals
Economic Benefits and Costs of Human Milk Feedings | Latch
Type: Blog
Topic(s): Bronchopulmonary Dysplasia (BPD) Late-Onset Sepsis Necrotizing Entercolitis (NEC) Neurodevelopmental Outcomes
Clinical Trial Evaluating the Effect of Prolact CR® on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth Weight Infants Surpasses the Halfway Point
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies on Prolact/Humavant CR Length of hospital stay
Benefits of an Exclusive Human Milk Diet Extend Beyond Reduction of NEC, Finds New Study Published in the Journal Breastfeeding Medicine
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Clinical Studies Necrotizing Entercolitis (NEC) Retinopathy of Prematurity (ROP)
Not finding the reference you’re looking for?
Email us at info@prolacta.com
